Tectonic Therapeutic has appointed Daniel Lochner as its new Chief Financial Officer (CFO). Dan brings extensive experience in corporate finance, business strategy, and operations, particularly within the healthcare and biopharmaceutical industries. He has held significant roles at Viatris’ Eye Care Division and Oyster Point Pharma, as well as serving as a Managing Director and Equity Portfolio Manager at Goldman Sachs. Dan's appointment coincides with Tectonic's focus on developing GPCR-targeted therapeutic proteins. The outgoing CFO, Christian Cortis, will stay until early July to ensure a smooth transition and will later serve as a strategic advisor. Tectonic is also set to complete its merger with AVROBIO by the end of the month.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.